Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation

Abstract

Long-term outcome was analyzed in 28 patients transplanted between 1989 and 1992 following busulfan and cyclophosphamide and who had busulfan levels studied. While there was no significant correlation of busulfan levels with diagnosis, patients who had received extensive prior chemotherapy had a significantly higher area under the curve (AUC; P = 0.02) and maximum busulfan levels (Cmax; P = 0.03). High AUC was associated with the development of hepatic veno-occlusive disease (P = 0.03) and with early transplant-related mortality (P = 0.06). No significant correlation of busulfan levels with relapse, late non-relapse death, late complications, nor event-free survival was detected. Bone Marrow Transplantation (2001) 27, 1121–1124.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    Article  CAS  PubMed  Google Scholar 

  2. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  3. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495

    CAS  PubMed  Google Scholar 

  4. Avalos BR, Klein JL, Kapoor N et al. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/Cy Bone Marrow Transplant 1993 12: 133–138

    CAS  PubMed  Google Scholar 

  5. Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myleoma Blood 1993 82: 2324–2328

    CAS  PubMed  Google Scholar 

  6. Grochow LB, Jones RJ, Brundett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61

    Article  CAS  PubMed  Google Scholar 

  7. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913

    Article  CAS  PubMed  Google Scholar 

  8. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  9. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  10. MacKichan JJ, Bechtel TP . Quantitation of busulfan in plasma by high performance liquid chromatography J Chromatogr 1990 532: 424–428.

    Article  CAS  PubMed  Google Scholar 

  11. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 11: 255–267

    Article  Google Scholar 

  12. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  PubMed  Google Scholar 

  13. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man Am J Pathol 1978 91: 545–570

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Clark JG, Crawford SW, Madtes DK, Sullivan KM . Obstructive lung disease after allogeneic marrow transplantation Ann Intern Med 1989 111: 368–376

    Article  CAS  PubMed  Google Scholar 

  15. Mann HB, Whitney DR . On a test of whether one of 2 random variables is stochastically larger than the other Ann Math Statist 1947 18: 50–60

    Article  Google Scholar 

  16. Kruskal WH, Wallis WA . Use of ranks in one criterion variance analysis J Am Stat Assoc 1952 47: 583–621

    Article  Google Scholar 

  17. Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 1–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copelan, E., Bechtel, T., Avalos, B. et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 27, 1121–1124 (2001). https://doi.org/10.1038/sj.bmt.1703047

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703047

Keywords

This article is cited by

Search

Quick links